An Article Published On Oncotarget Reveals The Effects Of E-Cigarettes On Oral Health

Previous studies have indicated that chemicals present in the smoke emitted from e-cigarettes were the major causes of health effects. However, recent studies involving a growing body of scientific data suggest otherwise. The University of Rochester Medical Center conducted a research that showed that health effects of e-cigarettes are caused by the vapors, which triggers cells to release inflammatory proteins that causes oral damage. Today, smokers are opting for e-cigarettes because they believe that they are less harmful to their health than conventional cigarettes. The study suggested that e-cigarettes are equally harmful as conventional cigarettes.

The study, which was led by the professor of environmental medicine at the UR School of Medicine and Dentistry, Irfan Rahman, exposed a 3D human non-smoker gum tissue to the vapors of a burning e-cigarette. The scientists found that the flavorings of the e-cigarettes contribute to the damage of oral cells. Fawad Javed, a post-doctoral student at Eastman Institute for Oral Health, noted that e-cigarettes contain nicotine, which is known for causing gum disease. Rahman said there is need for more research to be conducted to improve the understanding of health effects caused by e-cigarettes. He also posited that there was need for manufacturers to disclose all the chemicals and products used to develop their products. This information will make consumers aware of the dangers of each ingredient.

Learn more: https://www.ncbi.nlm.nih.gov/pmc/journals/1558/

Oncotarget is a peer-reviewed journal that publishes papers on cancer and oncology-related topics. The international journal focuses on various topics such as the pathological basis of all types of cancer, certain targets for therapy and treatment processes used to improve the lives of cancer patients. Oncotarget seeks to maximize the impact of management programs as well as new therapeutic protocols and agents on patient perspectives like adherence, quality of life and satisfaction. The journal publishes exceptional research findings on new and existing therapies. Oncotarget seeks to determine the usage of targeted therapies to define their acceptance by the healthcare professional and patients. The editors-in-chief of Oncortaget are Mikhail Blagosklonny and Andrei Gudkov. Notably, all manuscripts are reviewed and edited by experienced professionals in their respective fields of specialization. Follow Oncotarget journal on Twitter.